These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38783803)

  • 1. [Advances of CAR-T cell therapy in treating colorectal cancer].
    Chao Z; Liu W; Liu Y
    Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1365-1379. PubMed ID: 38783803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in CAR-T cells therapy for colorectal cancer.
    Qin X; Wu F; Chen C; Li Q
    Front Immunol; 2022; 13():904137. PubMed ID: 36238297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
    Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
    Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA
    Zhang C; Wang Z; Yang Z; Wang M; Li S; Li Y; Zhang R; Xiong Z; Wei Z; Shen J; Luo Y; Zhang Q; Liu L; Qin H; Liu W; Wu F; Chen W; Pan F; Zhang X; Bie P; Liang H; Pecher G; Qian C
    Mol Ther; 2017 May; 25(5):1248-1258. PubMed ID: 28366766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
    Wang H; Pan W
    Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
    Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
    Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
    Front Immunol; 2021; 12():782775. PubMed ID: 34790207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
    Wagner J; Wickman E; DeRenzo C; Gottschalk S
    Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
    Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
    J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    Hege KM; Bergsland EK; Fisher GA; Nemunaitis JJ; Warren RS; McArthur JG; Lin AA; Schlom J; June CH; Sherwin SA
    J Immunother Cancer; 2017; 5():22. PubMed ID: 28344808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in CAR-T-cell therapy in T-cell malignancies.
    Zheng R; Zhu X; Xiao Y
    J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
    Li Y; Hu Z; Li Y; Wu X
    Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.